The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
How Golden Staph Breaks Down Our Immune Defenses
A new study shows how golden staph identifies key immune cells and 'nukes' our body's immune response when it enters our skin.
Cipla Gets FDA Approval For Generic HIV Drug
Tentative approval for a generic HIV drug for use outside of the United States has been granted to Indian manufacturer Cipla.
MSF Treats First CMV Patients With Oral Drugs
Through a deal brokered with drug manufacturer Roche, CMV patients in Myanmar now need not endure painful injections directly into the eye.
7 Must-Read Stories In July 2014
A round-up of our top stories in July 2014; spanning ancient fossils to cosmic rays and the most high profile retraction in recent years.
India’s Spending Cuts Will Hurt Already Inadequate Health Services
A commentary published in The BMJ has warned that the recently announced health spending cuts will weaken India's public health system.
Hong Kong Doctors Use Microwaves To Treat Liver Cancer
A new type of FDA-approved high efficiency microwave coagulation system has now been tested in Asia by doctors from the University of Hong Kong Li Ka Shing Faculty of Medicine.
Cost Effective To Track Hepatitis B Carriers
A study has determined that monitoring inactive chronic hepatitis B carriers is a cost-effective strategy for managing the disease in China.
Antivirals Reduce Liver Disease Risk
Two independent studies show that treating hepatitis B early with antiviral drugs can reduce the risk of developing liver disease.
Gilead Allows India & China To Produce Generic HIV/HBV Drug
An agreement with the Medicines Patent Pool allows generics manufacturers in India and China to produce Gilead's HBV and HIV drug, tenofovir alafenamide.